International Journal of Gynecological Cancer最新文献

筛选
英文 中文
Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]. “dostarlimab治疗早期错配修复缺陷子宫内膜样子宫内膜腺癌的疗效、安全性和耐受性的2b期、开放标签、单臂、多中心试验研究”[International Journal of Gynecological Cancer vol . 35 Issue 4(2025) 101644]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-11 DOI: 10.1016/j.ijgc.2025.101961
Andreas Obermair, Val Gebski, Jeffrey Goh, Anna Kuchel, Alison Brand, Blossom Mak, Orla McNally, Eva Baxter, Thomas Jobling, Linda Mileshkin
{"title":"Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].","authors":"Andreas Obermair, Val Gebski, Jeffrey Goh, Anna Kuchel, Alison Brand, Blossom Mak, Orla McNally, Eva Baxter, Thomas Jobling, Linda Mileshkin","doi":"10.1016/j.ijgc.2025.101961","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101961","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101961"},"PeriodicalIF":4.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to 'Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101640]. 对“影响外科医生在卵巢癌细胞减少手术中进行回肠造口转移及相关并发症决定的因素”的更正[International Journal of Gynecological cancer Volume 35 Issue 4(2025) 101640]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-11 DOI: 10.1016/j.ijgc.2025.101959
Liat Hogen, Thirushi Siriwardena, Lina Salman, Marcus Q Bernardini, Sarah E Ferguson, Stephane Laframboise, Genevieve Bouchard-Fortier, Eshetu G Atenafu, Taymaa May
{"title":"Erratum to 'Factors influencing surgeons' decision for diverting ileostomy and associated complications in ovarian cancer cytoreductive surgery' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101640].","authors":"Liat Hogen, Thirushi Siriwardena, Lina Salman, Marcus Q Bernardini, Sarah E Ferguson, Stephane Laframboise, Genevieve Bouchard-Fortier, Eshetu G Atenafu, Taymaa May","doi":"10.1016/j.ijgc.2025.101959","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101959","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101959"},"PeriodicalIF":4.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to 'Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status' [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809]. 对“晚期上皮性卵巢癌的细胞减少手术:由临床变量、同源重组和BRCA状态指导的现实世界分析”的更正[International Journal of Gynecological cancer卷35第6期(2025)101809]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-11 DOI: 10.1016/j.ijgc.2025.101958
Eliya Shachar, Yael Raz, Gilat Rotkop, Uriel Katz, Ido Laskov, Nadav Michan, Dan Grisaru, Ido Wolf, Tamar Safra
{"title":"Corrigendum to 'Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status' [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809].","authors":"Eliya Shachar, Yael Raz, Gilat Rotkop, Uriel Katz, Ido Laskov, Nadav Michan, Dan Grisaru, Ido Wolf, Tamar Safra","doi":"10.1016/j.ijgc.2025.101958","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101958","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101958"},"PeriodicalIF":4.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to 'Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651]. “大量淋巴血管间隙侵犯对手术期子宫内膜样子宫内膜腺癌首次复发位置的影响”[国际妇科癌症杂志,第35卷第4期(2025)101651]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-06 DOI: 10.1016/j.ijgc.2025.101962
Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, Ben Davidson, Lora H Ellenson, Qin Zhou, Alexia Iasonos, Jennifer J Mueller, Kaled Alektiar, Vicky Makker, Jacqueline Feinberg, Evan Smith, Sarah H Kim, Sana Hatoum, Mario M Leitao, Nadeem R Abu-Rustum, Ane Gerda Z Eriksson
{"title":"Erratum to 'Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651].","authors":"Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, Ben Davidson, Lora H Ellenson, Qin Zhou, Alexia Iasonos, Jennifer J Mueller, Kaled Alektiar, Vicky Makker, Jacqueline Feinberg, Evan Smith, Sarah H Kim, Sana Hatoum, Mario M Leitao, Nadeem R Abu-Rustum, Ane Gerda Z Eriksson","doi":"10.1016/j.ijgc.2025.101962","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101962","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101962"},"PeriodicalIF":4.1,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to 'Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertility-sparing approach: an analysis of the ETERNITY project' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101643]. 对“早期宫颈癌bbb2cm化疗计划生育保留方法:对ETERNITY项目的分析”的勘误[International Journal of Gynecological caNcer卷35第4期(2025)101643]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-05 DOI: 10.1016/j.ijgc.2025.101960
Giorgio Bogani, Giovanni Scambia, Mario Malzoni, Jvan Casarin, Giuseppe Vizzielli, Frédéric Amant, Francesco Raspagliesi
{"title":"Erratum to 'Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertility-sparing approach: an analysis of the ETERNITY project' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101643].","authors":"Giorgio Bogani, Giovanni Scambia, Mario Malzoni, Jvan Casarin, Giuseppe Vizzielli, Frédéric Amant, Francesco Raspagliesi","doi":"10.1016/j.ijgc.2025.101960","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101960","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101960"},"PeriodicalIF":4.1,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to 'Controversies in malignant ovarian germ cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101670]. “恶性卵巢生殖细胞肿瘤的争议”的勘误[国际妇科癌症杂志第35卷第3期(2025)101670]。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-04 DOI: 10.1016/j.ijgc.2025.101954
Michael J Seckl, Baljeet Kaur, Ehsan Ghorani, Alice Bergamini, Giorgia Mangili
{"title":"Erratum to 'Controversies in malignant ovarian germ cell tumors' [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101670].","authors":"Michael J Seckl, Baljeet Kaur, Ehsan Ghorani, Alice Bergamini, Giorgia Mangili","doi":"10.1016/j.ijgc.2025.101954","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101954","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101954"},"PeriodicalIF":4.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HPV-associated and HPV-independent vulvar squamous cell carcinoma: is there an impact of resection margins on local recurrence? hpv相关和不相关的外阴鳞状细胞癌:切除边缘对局部复发有影响吗?
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-01 Epub Date: 2025-03-05 DOI: 10.1016/j.ijgc.2025.101757
Marilyn Boo, Lynn Sadler, Susan Bigby, Lois Eva
{"title":"HPV-associated and HPV-independent vulvar squamous cell carcinoma: is there an impact of resection margins on local recurrence?","authors":"Marilyn Boo, Lynn Sadler, Susan Bigby, Lois Eva","doi":"10.1016/j.ijgc.2025.101757","DOIUrl":"10.1016/j.ijgc.2025.101757","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the impact of resection margins on the first local recurrence of vulvar squamous cell carcinoma, stratified by human papillomavirus (HPV) status: HPV-associated (HPV-A) and HPV-independent (HPV-I). It also investigated the association between precursor lesions of vulvar squamous cell carcinoma at the resection margins and the risk of first local vulvar squamous cell carcinoma recurrence.</p><p><strong>Methods: </strong>This was a retrospective single-center clinicopathological case note review of patients treated with primary surgery for vulvar squamous cell carcinoma between January 1990 and December 2020, with follow-up until February 2024. The impact of pathological margins on first local recurrence was assessed for HPV-A and HPV-I tumors separately in univariable and multi-variable survival analyses.</p><p><strong>Results: </strong>A total of 360 vulvar squamous cell carcinoma cases were identified. Local recurrences were reported in 12 of 166 (7.2%) HPV-A and 53 of 194 (27.3%) HPV-I tumors (p < .001). Pathological margins <8 mm were significantly associated with increased local recurrence in HPV-I vulvar squamous cell carcinoma, with both univariable (HR 2.34, 95% CI 1.33-4.10, p = .003) and multi-variable analysis (adjusted HR 2.06, 95% CI 1.14 to 3.71, p = .0017) confirming this association. No significant association was observed in HPV-A vulvar squamous cell carcinoma (HR 0.70, 95% CI 0.22 to 2.24, p = .55). The number of HPV-A recurrences precluded multi-variable analysis. After stratifying by HPV sub-type, there was no association between precursors at the margins and local recurrence.</p><p><strong>Conclusions: </strong>Local recurrences are more common in HPV-I than HPV-A vulvar squamous cell carcinoma. Surgical margins may not influence the risk of local recurrence in HPV-A vulvar squamous cell carcinoma. However, in HPV-I vulvar squamous cell carcinoma, narrow resection margins of <8 mm appear to increase the risk of local recurrence. Therefore, HPV status should be incorporated into management protocols to risk-stratify follow-up care.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101757"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of sensitivity for Risk of Ovarian Malignancy Algorithm (ROMA) and Assessment of Different NEoplasias in the adneXa (ADNEX) model for predicting ovarian cancer in a woman with adnexal masses. 比较卵巢恶性肿瘤风险算法(ROMA)和不同肿瘤在ADNEX (ADNEX)模型中预测患有附件肿块女性卵巢癌的敏感性。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1016/j.ijgc.2025.101827
Pakorn Tangjanyatham, Woraphot Chaowawanit
{"title":"Comparison of sensitivity for Risk of Ovarian Malignancy Algorithm (ROMA) and Assessment of Different NEoplasias in the adneXa (ADNEX) model for predicting ovarian cancer in a woman with adnexal masses.","authors":"Pakorn Tangjanyatham, Woraphot Chaowawanit","doi":"10.1016/j.ijgc.2025.101827","DOIUrl":"10.1016/j.ijgc.2025.101827","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA) and the Assessment of Different NEoplasias in the adneXa (ADNEX) model in predicting ovarian cancer in women presenting with adnexal masses METHODS: A prospective diagnostic study was conducted at the Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Thailand. A total of 110 women with adnexal masses confirmed by ultrasound were enrolled. Pre-operative transvaginal ultrasound findings, serum CA125, and HE4 levels were used to evaluate the diagnostic performance of the ROMA and ADNEX models, with histopathological examination as the reference standard. The ADNEX model applied a 10% malignancy risk cutoff.</p><p><strong>Results: </strong>Using a 10% cutoff, the ADNEX model achieved a sensitivity of 91.9% and a specificity of 65.7%. In comparison, ROMA demonstrated a sensitivity of 64.8% and a specificity of 86.3%. The combined use of ADNEX and ROMA did not significantly improve diagnostic specificity. The receiver operating characteristic analysis for the ADNEX model showed an area under the curve of 0.83, indicating good diagnostic accuracy. The optimal threshold for malignancy risk was identified at a 13.8% cutoff, balancing sensitivity and specificity.</p><p><strong>Conclusions: </strong>The ADNEX model, with a 10% malignancy risk cutoff, provides superior sensitivity in diagnosing ovarian cancer in adnexal mass cases and could significantly contribute to early detection strategies. However, its lower specificity highlights the need for cautious interpretation. Further studies are warranted to refine these models and enhance their applicability across diverse clinical environments.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 6","pages":"101827"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining the heterogeneity of mismatch repair-deficient endometrial cancer. 改善错配修复缺陷子宫内膜癌的异质性。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1016/j.ijgc.2025.101830
Caio Guilherme Souza Prado, Mariana Carvalho Gouveia, Mariana Scaranti
{"title":"Refining the heterogeneity of mismatch repair-deficient endometrial cancer.","authors":"Caio Guilherme Souza Prado, Mariana Carvalho Gouveia, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101830","DOIUrl":"10.1016/j.ijgc.2025.101830","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101830"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial. 在ENGOT-EN6-NSGO/GOG3031/RUBY试验中,错配修复缺陷/微卫星不稳定性高的原发性晚期或复发性子宫内膜癌患者亚群接受多司他利单抗联合化疗与单纯化疗治疗的患者报告结果比较。
IF 4.1 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-06-01 Epub Date: 2025-04-19 DOI: 10.1136/ijgc-2024-005484
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak, Robert Holloway, Dominik Denschlag, Tashanna Myers, Anna M Thijs, Kathryn P Pennington, Lucy Gilbert, Evelyn Fleming, Oleksandr Zub, Lisa M Landrum, Beyhan Ataseven, Radhika Gogoi, Iwona Podzielinski, Noelle Cloven, Bradley J Monk, Sudarshan Sharma, Thomas J Herzog, Ashley Stuckey, Bhavana Pothuri, Angeles Alvarez Secord, Dana Chase, Veena Vincent, Oren Meyers, Jamie Garside, Mansoor Raza Mirza, Destin Black
{"title":"Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.","authors":"Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak, Robert Holloway, Dominik Denschlag, Tashanna Myers, Anna M Thijs, Kathryn P Pennington, Lucy Gilbert, Evelyn Fleming, Oleksandr Zub, Lisa M Landrum, Beyhan Ataseven, Radhika Gogoi, Iwona Podzielinski, Noelle Cloven, Bradley J Monk, Sudarshan Sharma, Thomas J Herzog, Ashley Stuckey, Bhavana Pothuri, Angeles Alvarez Secord, Dana Chase, Veena Vincent, Oren Meyers, Jamie Garside, Mansoor Raza Mirza, Destin Black","doi":"10.1136/ijgc-2024-005484","DOIUrl":"10.1136/ijgc-2024-005484","url":null,"abstract":"<p><strong>Objective: </strong>In the ENGOT-EN6-NSGO/GOG3031/RUBY trial, dostarlimab+carboplatin-paclitaxel demonstrated significant improvement in progression free survival and a positive trend in overall survival compared with placebo+carboplatin-paclitaxel, with manageable toxicity, in patients with primary advanced or recurrent endometrial cancer. Here we report on patient-reported outcomes in the mismatch repair-deficient/microsatellite instability-high population, a secondary endpoint in the trial.</p><p><strong>Methods: </strong>Patients were randomized 1:1 to dostarlimab+carboplatin-paclitaxel or placebo+carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab or placebo monotherapy every 6 weeks for ≤3 years or until disease progression. Patient-reported outcomes, assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Endometrial Cancer Module, were prespecified secondary endpoints. A mixed model for repeated measures analysis, a prespecified exploratory analysis, was conducted to generate least-squares means to compare between-treatment differences while adjusting for correlations across multiple time points within a patient and controlling for the baseline value. Results are provided with 2-sided, nominal p values.</p><p><strong>Results: </strong>Of 494 patients enrolled, 118 were mismatch repair-deficient/microsatellite instability-high. In this population, mean change from baseline to end of treatment showed visual improvements in global quality of life (QoL), emotional and social function, pain, and back/pelvis pain for dostarlimab+carboplatin-paclitaxel. Meaningful differences (least-squares mean [standard error]) favoring the dostarlimab arm were reported for change from baseline to end of treatment for QoL (14.7 [5.45]; p=0.01), role function (12.7 [5.92]); p=0.03), emotional function (14.3 [4.92]; p<0.01), social function (13.5 [5.43]; p=0.01), and fatigue (-13.3 [5.84]; p=0.03).</p><p><strong>Conclusions: </strong>Patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer receiving dostarlimab+carboplatin-paclitaxel demonstrated improvements in several QoL domains over patients receiving placebo+carboplatin-paclitaxel. The observed improvements in progression free survival and overall survival while improving or maintaining QoL further supports dostarlimab+carboplatin-paclitaxel as a standard of care in this setting. Trial registration ClinicalTrials.govNCT03981796.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101852"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信